A phase I study of KTN-0158 for the treatment of mast cell related inflammatory diseases
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2015
At a glance
- Drugs CDX-0158 (Primary)
- Indications Cancer; Inflammation
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2015 According to a Kolltan Pharmaceuticals media release, the company plans to file an investigational new drug application (IND) for KTN0158 with the FDA in the Q4 of 2015, followed by the initiation of cancer clinical trials in 2016. The company also expects a second IND filing for KTN0158 for neurofibromatosis 1 (NF1) in 2016.
- 05 Aug 2015 According to a Kolltan Pharmaceuticals media release, this trial is expected to begin in early 2016.
- 08 Jul 2015 New trial record